Cupid Ltd Q3 FY2023 Concall Summary

Key Takeaways

• Condom business anchors the story, but growth is price-led: Male condom capacity is ~95% utilized with no room to expand, so near-term revenue improvement must come from better pricing and mix, not volume.
• IVD is a FY25 story, not an FY23 one: The division generated only ₹12 lakh in sales this quarter and carries no order book; management targets profitability in Q1 FY24 and ₹50–100 crore revenue only by FY25.
• Raw material tailwinds are real and immediate: Silicone oil prices crashed >20% and foil/packaging declined 7–8%, with lower input costs expected to persist at least until June 2023, directly supporting margins.
• Q4 FY23 profit commitment set a high bar: Management guided for a minimum ₹10 crore profit and 20% sequential top-line and bottom-line growth, a specific near-term test of execution.
• What to watch next quarter: Whether the Q4 profit commitment is met, the size and timing of the South Africa and Brazil tenders, and any progress on WHO/CE mark certifications that would unlock IVD exports.

Condom Business: Capacity-Limited but Margin-Rich

• Male condom plant is full: Capacity utilization sits at ~95% and existing plant space is fully occupied, so volume growth is capped; revenue improvement must come from better pricing and product mix.
• Female condom capacity is available: Spare capacity exists, but demand generation depends on slow-moving government procurement cycles in South Africa and Brazil.
• Tender pipeline is the growth catalyst: Big male condom tenders are expected later in the year from South Africa, Tanzania, and India; South Africa's second-year requirements under a three-year contract were expected in the first week of February.
• Brazil female condom tender is a political wildcard: The presidential election has delayed the budget until end of March, and the government's quantity and volume requirements remain unclear; an announcement is expected in April, and only then will the tender size be known.

Om Garg: “The improvement will come from better pricing, better revenues from the condom business, and we do have spare capacity for female condoms.”

IVD: Early-Stage Build with a FY25 Payoff

• Commercial operations began, but revenue is negligible: IVD sales in the Oct–Dec quarter were only ₹12 lakh, with no order book yet; the division is servicing private-sector orders as they come and cannot yet bid for central government tenders, which require three years of manufacturing experience.
• Certifications are the gate to exports: WHO and CE mark applications were submitted during the quarter, and ISO 13485 certification is already in hand; export sales are delayed until those marks are received.
• Profitability is still negative: The IVD segment is yet to make a profit; management expects it to turn profitable in Q1 FY24, with FY24 revenue targeted at ₹5–10 crore, dependent on international developments and certifications.
• FY25 ambition is material: Management targets ₹50–100 crore turnover from IVD alone in FY25, a step-change that hinges on winning export tenders once WHO prequalification and CE marks are secured.

Om Garg: "In the year '25, we expect INR 50 crores to INR 100 crore sturnover in FY '25."

Raw Material Costs: A Margin Tailwind with a Shelf Life

• Input prices are falling across the board: Silicone oil prices declined >20% due to an economic slowdown in China, foil and packing material costs fell 7–8%, partially offset by a 5–7% increase in latex prices during the quarter.
• Latex prices are expected to ease soon: Management expects the downward trend to resume after the rainy season in Kerala starting from May.
• Favorable pricing has visibility through mid-2023: Lower prices are expected to continue at least until June 2023, with hopes the downward trend persists through calendar 2023; the calendar 2024 trend is not yet clear.
• Procurement is locked in: Raw material procurement has been secured for the next six months, through June.

Om Garg: “According to the current indication, the lower prices will continue at least until June of this year. And we are hoping that this downward trend would continue for the rest of 2023, what would be the trend in calendar year '24 is not yet clear.”

Strategic Optionality: Contract Manufacturing, US FDA, and M&A

• Singapore contract manufacturing deal is slow but alive: Discussions are ongoing with a Singapore-based pharma company for contract manufacturing of two patented diabetes-detection products under Cupid's IVD vertical; the party has visited the plant and wants manufacturing done in India, but discussions are slower than expected and no quantities or pricing have been disclosed.
• US manufacturing inquiry is a new lead: A US company approached Cupid last month wanting to manufacture their products in India; they have visited the factory and discussions have been initiated.
• US FDA female condom application faces a clinical hurdle: The US FDA is reviewing Cupid's application and has requested a new clinical study in the US using US participants, replacing the earlier study.
• Acquisition interest exists but is early: A few parties have expressed interest in acquiring Cupid; management is talking to them but there is no significant development as of now.

Guidance & Commitments

Key Metrics